However, in the US, UK, and many parts of Europe, the patent protection for semaglutide would last till 2031 and beyond, as they have patent term extension mechanisms that can be used to extend the protection period
The most common systemic side effects nausea, vomiting, diarrhea come from the medication itself, not from injection technique, and tend to be strongest in the first weeks or after a dose increase
1 For patients with symptomatic joint hypermobility satisfying neither the new hypermobile EDS criteria nor another specific condition, the 2017 classification introduced hypermobility spectrum disorders
Future studies in real-world settings may prove beneficial in gauging the efficacy of semaglutide more realistically
Clinical data shows average weight loss of 37 pounds with semaglutide combined with lifestyle changes
2006-2026 NHC.com, LLC, all rights reserved